Context Therapeutics price target raised to $7 from $4 at Piper Sandler

Piper Sandler raised the firm’s price target on Context Therapeutics (CNTX) to $7 from $4 and keeps an Overweight rating on the shares after the company reported Q4/FY25 earnings and provided a pipeline update. The firm is raising its price target due to the amended Integral agreement, moving its discounted cash flow forward, and lower operating expenses than originally estimated.